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Abstract: The aim of this study was to demonstrate the value of immunocytochemical staining of Ki67 antigen expression in
blast cells of children with acute myeloid leukemia (AML) and to evaluate its correlation with treatment failure. The material
included bone marrow specimens obtained during induction treatment from 46 children treated for AML between 1998-2003.
Immunocytochemical staining for Ki67 was based on the ABC technique. Expression of Ki67 antigen on day 0 of induction
treatment was confirmed in all patients. The percentage of immunopositive blasts ranged from 88.4% to 99.8% (mean 91.8%).
On day 15, according to chemotherapy response, patients were divided into two groups: G1 - 36 children who responded to
induction treatment and reached remission (blast level  5%, low risk group) and G2 - 10 patients who did not meet remission
criterion (blast level > 5%) and were assigned to the high risk (HR) group. Out of 10 children assigned to this group, Ki67 expression
in blast cells was confirmed in 4 cases. The fraction of immunopositive blasts ranged from 78.4% to 88.6%. In the other 6 cases,
blasts were Ki67-negative. In 12-month period after beginning the treatment, 18 cases of treatment failure (including 7 deceases)
were observed in both groups. Five deaths, observed in the HR group, concerned the patients characterized by Ki67-negative blasts.
The results indicate a possible correlation between the Ki67-immunonegative blast pattern on day 15 of treatment induction and
early decease of AML children assigned to HR group. (www.cm-uj.krakow.pl/FHC)
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Introduction
Acute myeloid leukemia (AML) constitutes up to 15%
of all leukemias in children [16]. Definition of AML
encompasses a number of proliferative diseases develo-
ping secondary to neoplastic transformation of non-lym-
phocytic and poorly differentiated bone marrow cells.
The current classification was established in 1976 by a
French-American-British (FAB) team [2]. Modified in
1985 by supplementation with erythroleukemia and
megakaryocytic leukemia [3, 4], it is based first of all on
morphological criteria related to neoplastically trans-
formed hematopoietic cells. 
In children with AML, among other factors, the
original leukocytosis in peripheral blood  50 G/l can be
regarded as unfavourable [20]. Patient age < 2 yr, forms
M4 and M5 [19] or genetic abnormalities are also used
to be listed [21, 24]. In the Polish Pediatric Leuke-
mia/Lymphoma Study Group, patients are included to
the high risk group if the M5 subtype is preliminarily
diagnosed or when leukemic blasts constitute > 5% nu-
cleated cells of bone marrow on day 15 after commenc-
ing the treatment (AML-98 regimen) [5, 6]. In our
observations, high risk group criteria are met by around
20% of patients [7]. Although the hematological re-
mission is obtained in 70%-85% of those patients on day
29, follow-up survival without relapses and decease can
be obtained in no more than 50% of patients [9]. This
may indicate that the high histological and clinical ma-
lignancy in this group has not yet been counteracted with
an appropriate therapeutic protocol. 
In earlier study performed in a group of children with
acute lymphoblastic leukaemia, we have found that the
presence of Ki67-positive blast cells before the start of
the treatment represents a potential index of favourable
prognosis and can assist qualification of the patients to
risk groups [14]. 
Ki67 antigen expression appears to occur in the
middle of the G1 phase of the cell cycle. It increases
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during the S and G2 phases to reach a peak during mitosis
[23]. The Ki67 molecule becomes rapidly hydrolysed
soon after the end of the M phase. Together with prolif-
erating cell nuclear antigen (PCNA), the Ki67 antigen is
one of the most sensitive markers of undifferentiated cell
proliferation [1, 10, 23]. It is absent during the G0 phase
- the stage at which neoplastic cells are totally unrespon-
sive to chemotherapy [23]. 
In line with the abovementioned findings, the aim of
the present report was to demonstrate the value of Ki67
antigen expression in blast cells of patients with AML
during chemotherapy regimen and to evaluate its corre-
lation with early treatment failure.
Materials and methods
Material used in this study consisted of bone marrow samples ob-
tained from children treated at the Department of Pediatric Oncology,
Hematology and Transplantology, Poznan´ University of Medical
Sciences, between 1998 and 2003. The research protocol was ap-
proved by the local Ethical Commission of the University. Sixty-five
children referred to our Department were included in the investiga-
tion. Bone marrow biopsies were performed in all of them and
evidence for neoplasia was found in 46 cases. The remaining 19
children, all of whom presented only one enlarged lymph node,
served as the control group. In this group, histological examination
of the enlarged node indicated an inflammatory response only.
Subsequent observation of the children for around 12 months in the
Outpatient Clinic for Hyperplastic Diseases, detected no clinical
traits of a neoplastic disease. 
Four children were diagnosed as AML type M0, 8 as AML M1,
26 as AML M2, 4 as AML M3 and 4 as AML M4. There were no
patients diagnosed with AML M5, M6 and M7 types. The relevant
data are presented in Table 1. 
Bone marrow, according to ANLL-98 protocol, was sampled on
days 0, 15 and 29 after starting the treatment. Its aspiration was
carried out under intravenous anesthesia (pethidine 1mg/kg b.w.,
midazolam 0.1mg/kg b.w.). The samples were collected from the pos-
terior superior iliac spine. The bone marrow smears were fixed in 96%
ethanol (30 min, room temperature) within 24 hours of sampling and
kept at -80˚C until immunophenotyping was performed.
Ki67 antigen detection involved an immunocytochemical proce-
dure with the use of mouse monoclonal antibodies against human
Ki67 (Dako, M 7187) and StreptABComplex/HRP technique ampli-
fied by the use of biotinylated tyramine (Dako Catalysed Signal
Amplification System, Peroxidase, K 1500). Heat-induced antigen
demasking pre-treatment was carried out (Target Retrieval Solution,
Dako S 1699) [15, 17, 18]. The endogenous peroxidase activity was
blocked by 10 min preincubation in 10% hydrogen peroxide. The
smears were then treated with anti-Ki67 antibodies, diluted 1:500,
for 12 h at 4˚C. Incubation with the secondary antibody (biotinylated
goat anti-mouse, Dako E 0433, diluted 1:300) was performed at room
temperature for 60 minutes. This was followed by the incubation with
diaminobenzidine (DAB, Dako S 3000). The number of immunoposi-
tive blasts, as compared to the total number of blast cells, was established
under a light microscope (magnification × 100). Quantitative analysis
was carried out using MultiScan® computer software.
Immunocytochemical staining of the following antigens was used
to verify leukemic and normal cells: HLA-DR, CD13, CD14, CD15,
CD33, CD34, CD41 and CD61 [9]. The diagnosis of AML remission
was confirmed by blood morphology (clinical remission), micro-
scopic analysis of subsequent bone marrow samples (May-Grüun-
wald-Giemsa staining, hematologic remission) and the second
immunophenotyping of bone marrow nucleated cells (immunologi-
cal remission).
In every case of Ki67 immunocytochemical detection, each la-
boratory test was performed at least twice. In addition, each exam-
ination of bone marrow was accompanied by positive and negative
controls [8, 13]. All results which were doubtful, nonspecific, or
difficult to interpret were excluded from the study.
Since the studied group was relatively small, the statistical ana-
lysis was based on the Fisher exact test.
Results
Expression of Ki67 antigen on day 0 of initial treatment
was confirmed in all patients with AML. The percentage
Fig. 1. Diagrammatic representation of the sample outcome.
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of immunopositive blasts ranged from 88.4% to 99.8%
(mean of 91.8% blast cells) and did not significantly
differ between AML subtypes. Ki67 was absent (< 5%
nucleated cells) in the normal hematopoietic cells of 19
children in the control group. 
The AML remission was diagnosed in 36 children
(78.3%, low risk group) on day 15 (mean 3.2% leukemic
cells). In 10 children (21.7%, high risk group) disease
progression was diagnosed (4 cases of AML type M1, 5
of M2 and 1 of M3, respectively) with a poor response
to cytoreducing treatment on days 15 and 29 of treatment
with cytosine arabinoside, idarubicin and etoposide (a
reduction of the bone marrow blast level by less than
5%). 
In 4 out of 10 children assigned to the high risk group,
Ki67 expression in blast cells was confirmed on day 15
(40.0%). The fraction of immunopositive blasts ranged
from 78.4% to 88.6%. In the remaining 6 cases (60.0%),
blasts were Ki67-negative.
During the observation period (12 months), 18 cases
of early leukemia treatment failure were noted. In the
low risk group one child died due to Pseudomonas
aeruginosa infection. In 7 cases, the subsequent bone
marrow examination was performed due to relapse of
the disease. It revealed Ki67-positive blasts (mean
88.5%) in 3 children and Ki67-immunonegative blast
pattern in the other 4 children. The treatment protocol
was changed to a more aggressive Ida-FLAG program
[11] followed by bone marrow transplantation and, ex-
cept of one Ki67 immunonegative patient, these children
are still alive in their second remission. In the high risk
group, 6 children died due to progression of the disease
resulting from the pan-drug resistance. Apart from one
child who was Ki67-positive on day 15, all other patients
revealed an immunonegative Ki67 blast pattern on that
day of treatment. The detailed information is presented
in Figure 1.
The probability of the first remission was significant-
ly higher in the low risk group patients (p=0.0001), but
independent from the initial Ki67 expression.
The distribution of mortality in high risk group pa-
tients was Ki67-dependent (regardless of AML type).
Statistical analysis of these children revealed that the
probability of permanent leukemia remission is signifi-
cantly higher in patients with Ki67-immunopositive
blast pattern on day 15 (p=0.0194). It has been also
shown that the risk of death following leukemia progres-
sion in patients with Ki67-immunonegative blast pattern
treated according to only ANLL-98 programme is sig-
nificantly higher (p= 0.0194) as compared to the patients
who were Ki67-negative but were treated according to
Ida-FLAG scheme.
Discussion
Ki67 antigen, which is regarded as a marker of prolif-
erative cells, has been identified as a free peptide in the
nucleus or complexed with DNA [12]. Despite the opti-
mal fixation and the amplified antigen detection, some
neoplastic cells in the G1 and G2 phases fail to reveal
immunocytochemical expression of the marker. In the
experimental study on cell populations with surface
phenotyping of human T-cell leukemia (Molt-4 human
leukemia cells), the cell cycle was arrested at G1 and G2
phases using 10 nM 12-0-tetra-decanoylphorbol-13-
acetate. When applied to cell cultures, it reduced Ki67
expression to nondetectable levels, if standard immuno-
cytochemical methods were employed [24]. Thus, some
cells with a relatively long G1 phase gradually lose their
ability to express Ki67 during G1 and G2. There is,
therefore, a population of G1 Ki67 negative blasts which
can still proliferate. 
The above observations correspond to results of the
present study. In the majority of the high risk group
children in whom Ki67-immunonegative blast pattern
has been detected on day 15 of induction regimen, the
treatment has ended in a failure. 
It is interesting that the high percentage of Ki67-posi-
tive blasts has been found in bone marrow before treat-
ment in all the children, regardless of AML type or future
complications. It seems to indicate that originally all
neoplastic cells in AML may exhibit high sensitivity to
chemotherapy. However, in the course of the undertaken
induction therapy the originally homogenous population
of blasts becomes selected into Ki67-positive and Ki67-
negative cells. At this stage of treatment, the most im-
portant day is the day 15, on which the potential to reach
stable remission may become determined. 
Table 1. Clinical characteristics and data on disease course in patients with acute myeloid leukaemia (AML)
Study
group AML type (markers)
Number of
patients Age (yr)
Risk group
HR (%) LR (%)
1 M0 (HLA-DR, CD33)  4 11.3  1.2 0 (0) 4 (100)
2 M1 (HLA-DR, CD13, CD33)  8 10.8  5.2 4 (50) 4 (50)
3 M2 (HLA-DR, CD13, CD33, CD15, CD34) 26 9.8  4.6 5 (19) 21 (81)
4 M3 (CD13, CD33, CD15)  4 8.9  4.8 1 (25) 3 (75)
5 M4 (HLA-DR, CD13, CD14, CD15, CD33)  4 9.4  6.7 0 (0) 4 (100)
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The present protocol of AML treatment (ANLL-98)
does not introduce Ida-FLAG regimen to children who
did not respond to induction treatment on day 15. It
becomes recommended when the AML relapse is rec-
ognised. In our study, seven early relapses were noted
in low risk patients. Although in 4 of them Ki67-negative
clone of blast cells was selected, 3 children have reached
the second remission and after bone marrow transplan-
tation they are still alive in their second remission. It
should be emphasized that such a remission was reached
only by the single child of high risk group who was
Ki67-negative on day 15 and had undergone the AML-
98, no-Ida-FLAG, protocol.
Without doubt, oncological treatment may be effec-
tive only when it is adjusted to aggressiveness of the
disease. Therefore, recognition of risk factors is of key
importance for designing the effective therapy in any
oncological disease. In this aspect, the AML status is less
favourable than that of ALL. This reflects less frequent
manifestation of AML and its higher pathogenetic vari-
ability. The selection of Ki67-negative clone of blasts
cells seems to be a potent unfavourable factor of child-
hood myeloid leukemia. However, introduction of Ida-
FLAG protocol to all children who are Ki67-negative on
day 15 needs a further multi-centre investigation.
In conclusion, Ki67 immunonegative blast pattern on
day 15 of the induction treatment in acute myeloid
leukemia may represent a new index of unfavourable
prognosis in the high risk group children. The obtained
results may also justify routine determination of Ki67
antigen before and during the treatment regimen of acute
myeloid leukemia.
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